drugset
drugset / Trial / NCT06083844

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

NCT06083844 ↗

Phase 2 Recruiting 20 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.

Timeline

Start
2023-12-12
Primary completion
2027-09-30
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — Intravenous
Subject Cyclophosphamide Other / unclassified — Oral
Subject Pembrolizumab Monoclonal antibody — Intravenous

Indications

ovarian cancer